
Bristol-Myers Squibb (BMY) Stock
Bristol-Myers Squibb Chart
Company Profile
Price: $53.90
Market Cap: $109.32B
Exchange: NYSE
CEO: Dr. Christopher S. Boerner Ph.D.
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 34.10K
Headquarters: New York, NY
Website: Bristol-Myers Squibb
Business Summary
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Bristol-Myers Squibb News
Bristol-Myers Squibb: Cobenfy's Strong Launch And 2025 Growth Outlook
Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and broad Medicaid/Medicare coverage, supporting its blockbuster potential in schizophrenia and future label expansions. Despite a recent share price decline, BMY's strategic cost reductions, debt repayments, and dividend commitments highlight its long-term growth and shareholder return focus. LOE risks for key drugs like Yervoy and Eliquis and cautious 2025 guidance suggest temporary volatility, justifying a "Hold" rating at the current share price.

Bristol Myers Squibb Announces Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--Bristol Myers Squibb Announces Positive Topline Results for Breyanzi in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma.

Bristol-Myers Squibb: Solid Q4 Earnings, But Weak Guidance And Patent Concerns Drive The Stock Down
Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and concerns over patent expirations for key drugs. CEO Chris Boerner's multiyear plan focuses on developing a 'growth portfolio' and pipeline execution, with promising approvals like subcutaneous Opdivo and Cobenfy. Despite significant debt and uncertainty, Bristol-Myers is a compelling contrarian buy if pipeline execution offsets the $25B at-risk revenue from patent expirations.

Bristol-Myers Squibb Company (BMY) Q4 2024 Earnings Conference Call Transcript
Bristol-Myers Squibb Company (NYSE:BMY ) Q4 2024 Earnings Conference Call February 6, 2025 8:00 AM ET Company Participants Chuck Triano - Senior Vice President, Investor Relations Chris Boerner - Board Chair & Chief Executive Officer David Elkins - Chief Financial Officer Adam Lenkowsky - Chief Commercialization Officer Samit Hirawat - Chief Medical Officer & Head of Global Drug Development Conference Call Participants Chris Schott - JPMorgan Luisa Hector - Berenberg Geoff Meacham - Citibank Chris Shibutani - Goldman Sachs Tim Anderson - Bank of America Mohit Bansal - Wells Fargo Securities Evan Seigerman - BMO Capital Markets Akash Tewari - Jefferies Terence Flynn - Morgan Stanley Courtney Breen - Bernstein Seamus Fernandez - Guggenheim Securities David Risinger - Leerink Partners Matt Phipps - William Blair Steve Scala - Cowen Kripa Devarakonda - Truist Securities Olivia Brayer - Cantor Fitzgerald James Shin - Deutsche Bank Sean McCutchen - Raymond James Alexandria Hammond - Wolfe Research Operator Welcome to the Bristol-Myers Squibb Fourth Quarter 2024 Earnings Conference Call. All participants will be in listen-only mode.

Here's What Key Metrics Tell Us About Bristol Myers (BMY) Q4 Earnings
Although the revenue and EPS for Bristol Myers (BMY) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance
Bristol Myers Squibb said it will slash $2 billion in costs by the end of 2027, expanding its ongoing cost savings effort to chart a path toward long-term growth. The company also issued a full-year 2025 guidance that fell short of Wall Street's expectations, as some of the company's older drugs face competition from cheaper generics.

What Analyst Projections for Key Metrics Reveal About Bristol Myers (BMY) Q4 Earnings
Besides Wall Street's top -and-bottom-line estimates for Bristol Myers (BMY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.

2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond
If there were an official hierarchy of qualities that dividend seekers should consider before investing in a stock, a company's underlying business would almost certainly come ahead of its yield. However, the two aren't mutually exclusive.

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--BMS Receives Positive CHMP Opinion for Opdivo plus Yervoy as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced HCC.

Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma.

10 Undervalued Dividend Growth Stocks: January 2025
I rank a selection of undervalued dividend growth stocks in Dividend Radar and present the ten top-ranked stocks for consideration. I use two valuation screens, one based on my fair value estimate, and another comparing each stock's forward dividend yield with its 5-year average dividend yield. To rank stocks, I do a quality assessment and sort candidates by quality scores, breaking ties with additional metrics.

Bristol-Myers Squibb Earnings
This section highlights Bristol-Myers Squibb's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
---|---|---|---|---|---|
Read Transcript | Q4 | 2024 | 2025-02-06 | $1.47 | $1.67 |
Read Transcript | Q3 | 2024 | 2024-10-31 | $1.49 | $1.80 |
Read Transcript | Q2 | 2024 | 2024-07-26 | $1.62 | $2.07 |
Read Transcript | Q1 | 2024 | 2024-04-25 | $-4.41 | $-4.40 |
Read Transcript | Q4 | 2023 | 2024-02-02 | $1.52 | $1.70 |
Read Transcript | Q3 | 2023 | 2023-10-26 | $1.76 | $2.00 |
Read Transcript | Q2 | 2023 | 2023-07-27 | $1.99 | $1.75 |
Read Transcript | Q1 | 2023 | 2023-04-27 | $1.98 | $2.05 |
Financial Statements
Access annual & quarterly financial statements for Bristol-Myers Squibb, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
---|---|---|---|---|---|
Revenue | $48.30B | $45.01B | $46.16B | $46.38B | $42.52B |
Cost of Revenue | $- | $10.69B | $10.14B | $9.94B | $11.77B |
Gross Profit | $48.30B | $34.31B | $36.02B | $36.45B | $30.75B |
Gross Profit Ratio | 100.00% | 76.24% | 78.04% | 78.57% | 72.31% |
Research and Development Expenses | $11.16B | $9.30B | $9.51B | $10.20B | $11.14B |
General and Administrative Expenses | $- | $6.28B | $- | $- | $- |
Selling and Marketing Expenses | $- | $1.40B | $7.81B | $7.69B | $7.66B |
Selling General and Administrative Expenses | $8.41B | $7.77B | $7.81B | $7.69B | $7.66B |
Other Expenses | $- | $- | $9.60B | $10.02B | $9.76B |
Operating Expenses | $19.57B | $17.89B | $26.92B | $27.91B | $28.57B |
Cost and Expenses | $19.57B | $28.41B | $37.05B | $37.85B | $40.34B |
Interest Income | $- | $- | $- | $- | $- |
Interest Expense | $- | $1.17B | $1.23B | $1.33B | $1.42B |
Depreciation and Amortization | $- | $9.81B | $10.29B | $10.76B | $10.49B |
EBITDA | $- | $19.42B | $19.23B | $20.19B | $5.04B |
EBITDA Ratio | 0.00% | 43.14% | 43.16% | 43.51% | 34.85% |
Operating Income | $28.73B | $17.24B | $10.33B | $10.16B | $5.13B |
Operating Income Ratio | 59.48% | 38.31% | 22.37% | 21.90% | 12.06% |
Total Other Income Expenses Net | $-37.11B | $-8.80B | $-10.64B | $-9.30B | $-7.42B |
Income Before Tax | $-8.38B | $8.44B | $7.71B | $8.10B | $-6.87B |
Income Before Tax Ratio | -17.35% | 18.75% | 16.71% | 17.46% | -16.16% |
Income Tax Expense | $554.00M | $400.00M | $1.37B | $1.08B | $2.12B |
Net Income | $-8.95B | $8.03B | $6.33B | $6.99B | $-8.99B |
Net Income Ratio | -18.53% | 17.83% | 13.71% | 15.08% | -21.16% |
EPS | $-4.41 | $3.88 | $2.97 | $3.15 | $-3.98 |
EPS Diluted | $-4.41 | $3.86 | $2.95 | $3.12 | $-3.98 |
Weighted Average Shares Outstanding | 2.03B | 2.07B | 2.13B | 2.22B | 2.26B |
Weighted Average Shares Outstanding Diluted | 2.03B | 2.08B | 2.15B | 2.25B | 2.26B |
SEC Filing | Source | Source | Source | Source | Source |
Income Statement Charts
Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | $11.89B | $12.20B | $11.87B | $11.48B | $10.97B | $11.23B | $11.34B | $11.41B | $11.22B | $11.89B | $11.65B | $11.98B | $11.62B | $11.70B | $11.07B | $11.07B | $10.54B | $10.13B | $10.78B | $7.95B |
Cost of Revenue | $2.96B | $5.40B | $2.93B | $2.75B | $2.51B | $2.88B | $2.57B | $2.59B | $2.35B | $2.72B | $2.47B | $2.36B | $2.29B | $2.45B | $2.84B | $2.91B | $2.50B | $2.70B | $3.66B | $2.49B |
Gross Profit | $8.94B | $6.80B | $8.93B | $8.73B | $8.46B | $8.35B | $8.77B | $8.81B | $8.87B | $9.17B | $9.18B | $9.63B | $9.33B | $9.25B | $8.23B | $8.16B | $8.04B | $7.43B | $7.12B | $5.45B |
Gross Profit Ratio | 75.13% | 55.74% | 75.29% | 76.08% | 77.15% | 74.38% | 77.37% | 77.27% | 79.02% | 77.12% | 78.79% | 80.34% | 80.29% | 79.05% | 74.34% | 73.71% | 76.26% | 73.35% | 66.03% | 68.63% |
Research and Development Expenses | $2.37B | $2.29B | $2.69B | $2.48B | $2.24B | $2.26B | $2.32B | $2.51B | $2.42B | $2.32B | $2.26B | $2.52B | $3.25B | $3.27B | $2.23B | $3.75B | $2.50B | $2.52B | $2.37B | $2.10B |
General and Administrative Expenses | $- | $- | $- | $673.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Selling and Marketing Expenses | $1.98B | $- | $2.37B | $1.40B | $2.00B | $- | $1.76B | $2.27B | $1.93B | $- | $- | $2.35B | $1.79B | $- | $1.67B | $2.72B | $1.71B | $1.63B | $1.61B | $1.73B |
Selling General and Administrative Expenses | $1.98B | $1.92B | $2.37B | $2.07B | $2.00B | $1.93B | $1.76B | $2.27B | $1.93B | $1.79B | $1.83B | $2.35B | $1.79B | $1.88B | $1.67B | $2.72B | $1.71B | $1.63B | $1.61B | $1.73B |
Other Expenses | $- | $458.00M | $401.00M | $-272.00M | $565.00M | $526.00M | $2.26B | $2.34B | $2.42B | $470.00M | $467.00M | $164.00M | $443.00M | $435.00M | $394.00M | $472.00M | $398.00M | $395.00M | $459.00M | $-94.00M |
Operating Expenses | $8.94B | $4.22B | $7.42B | $6.83B | $4.25B | $6.45B | $6.34B | $7.12B | $6.77B | $6.53B | $6.51B | $7.29B | $7.58B | $7.70B | $6.40B | $9.00B | $6.70B | $6.54B | $6.34B | $4.89B |
Cost and Expenses | $9.60B | $9.62B | $10.35B | $9.57B | $6.75B | $9.32B | $8.90B | $9.71B | $9.12B | $9.24B | $8.98B | $9.64B | $9.88B | $10.15B | $9.24B | $11.91B | $9.20B | $9.24B | $10.00B | $7.38B |
Interest Income | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Interest Expense | $505.00M | $521.00M | $425.00M | $316.00M | $280.00M | $282.00M | $288.00M | $294.00M | $299.00M | $313.00M | $326.00M | $323.00M | $328.00M | $330.00M | $353.00M | $355.00M | $346.00M | $357.00M | $362.00M | $279.00M |
Depreciation and Amortization | $2.59B | $2.56B | $2.56B | $2.46B | $2.45B | $2.45B | $2.45B | $2.50B | $2.65B | $2.54B | $2.65B | $2.64B | $2.74B | $2.64B | $2.73B | $2.53B | $2.65B | $2.56B | $2.48B | $1.06B |
EBITDA | $4.77B | $4.37B | $-8.54B | $4.45B | $4.85B | $4.59B | $5.50B | $4.65B | $5.08B | $5.36B | $5.50B | $4.82B | $5.48B | $5.32B | $4.98B | $-7.36B | $5.24B | $4.63B | $2.53B | $1.40B |
EBITDA Ratio | 40.14% | 42.17% | 37.48% | 36.14% | 38.44% | 41.21% | 44.95% | 41.33% | 47.25% | 45.32% | 43.58% | 41.41% | 46.31% | 40.00% | 49.59% | 24.06% | 44.01% | 46.03% | 31.35% | 22.88% |
Operating Income | $2.17B | $2.58B | $3.87B | $1.68B | $4.21B | $4.16B | $2.84B | $2.37B | $2.71B | $2.82B | $2.49B | $2.55B | $2.66B | $2.13B | $2.82B | $137.00M | $1.98B | $2.10B | $903.00M | $756.00M |
Operating Income Ratio | 18.26% | 21.18% | 32.63% | 14.67% | 38.44% | 37.04% | 25.05% | 20.79% | 24.18% | 23.74% | 21.39% | 21.24% | 22.85% | 18.23% | 25.49% | 1.24% | 18.82% | 20.77% | 8.38% | 9.52% |
Total Other Income Expenses Net | $-496.00M | $-1.30B | $-2.86B | $-1.95B | $-2.08B | $-2.30B | $-1.90B | $-2.21B | $-2.31B | $-731.00M | $-1.02B | $-2.82B | $-2.14B | $-5.00M | $-1.81B | $-1.66B | $-2.04B | $-1.65B | $-1.23B | $-885.00M |
Income Before Tax | $1.68B | $1.29B | $-11.52B | $1.67B | $2.14B | $1.86B | $2.77B | $1.86B | $2.21B | $1.96B | $1.69B | $1.86B | $2.16B | $1.55B | $2.53B | $-10.45B | $2.26B | $1.63B | $-304.00M | $-129.00M |
Income Before Tax Ratio | 14.09% | 10.54% | -97.06% | 14.59% | 19.49% | 16.56% | 24.43% | 16.30% | 19.69% | 16.47% | 14.48% | 15.50% | 18.56% | 13.27% | 22.85% | -94.43% | 21.41% | 16.06% | -2.82% | -1.62% |
Income Tax Expense | $461.00M | $-398.00M | $392.00M | $-88.00M | $203.00M | $-218.00M | $503.00M | $-166.00M | $601.00M | $529.00M | $404.00M | $-514.00M | $605.00M | $492.00M | $501.00M | $-424.00M | $379.00M | $1.71B | $462.00M | $931.00M |
Net Income | $1.21B | $1.68B | $-11.91B | $1.76B | $1.93B | $2.07B | $2.26B | $2.02B | $1.61B | $1.42B | $1.28B | $2.37B | $1.55B | $1.05B | $2.02B | $-10.03B | $1.87B | $-85.00M | $-775.00M | $-1.06B |
Net Income Ratio | 10.18% | 13.77% | -100.39% | 15.35% | 17.58% | 18.47% | 19.95% | 17.73% | 14.32% | 11.95% | 10.97% | 19.79% | 13.30% | 9.01% | 18.25% | -90.59% | 17.76% | -0.84% | -7.19% | -13.29% |
EPS | $0.60 | $0.83 | $-5.89 | $0.87 | $0.94 | $0.99 | $1.08 | $0.96 | $0.75 | $0.67 | $0.60 | $1.10 | $0.70 | $0.47 | $0.90 | $-4.45 | $0.83 | $-0.04 | $-0.34 | $-0.55 |
EPS Diluted | $0.60 | $0.83 | $-5.89 | $0.87 | $0.93 | $0.99 | $1.07 | $0.95 | $0.75 | $0.66 | $0.59 | $1.07 | $0.69 | $0.47 | $0.89 | $-4.45 | $0.82 | $-0.04 | $-0.34 | $-0.55 |
Weighted Average Shares Outstanding | 2.03B | 2.03B | 2.02B | 2.03B | 2.06B | 2.09B | 2.10B | 2.11B | 2.13B | 2.13B | 2.15B | 2.15B | 2.22B | 2.23B | 2.24B | 2.25B | 2.26B | 2.26B | 2.26B | 1.91B |
Weighted Average Shares Outstanding Diluted | 2.03B | 2.03B | 2.02B | 2.03B | 2.06B | 2.10B | 2.11B | 2.12B | 2.15B | 2.15B | 2.16B | 2.22B | 2.24B | 2.25B | 2.27B | 2.25B | 2.29B | 2.26B | 2.26B | 1.92B |
SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
---|---|---|---|---|---|
Cash and Cash Equivalents | $10.35B | $11.46B | $9.12B | $13.98B | $14.55B |
Short Term Investments | $513.00M | $816.00M | $130.00M | $3.24B | $1.28B |
Cash and Short Term Investments | $10.86B | $12.28B | $9.12B | $13.98B | $14.55B |
Net Receivables | $10.75B | $15.26B | $13.94B | $12.52B | $8.50B |
Inventory | $2.56B | $2.66B | $2.34B | $2.10B | $2.07B |
Other Current Assets | $5.62B | $1.56B | $1.74B | $1.29B | $5.58B |
Total Current Assets | $29.78B | $31.77B | $27.27B | $33.26B | $30.19B |
Property Plant Equipment Net | $7.14B | $8.04B | $7.47B | $6.97B | $6.75B |
Goodwill | $21.72B | $21.17B | $21.15B | $20.50B | $20.55B |
Intangible Assets | $23.31B | $27.07B | $36.35B | $42.77B | $53.24B |
Goodwill and Intangible Assets | $45.03B | $48.24B | $57.50B | $63.28B | $73.79B |
Long Term Investments | $- | $2.50B | $2.19B | $2.71B | $4.51B |
Tax Assets | $4.24B | $2.77B | $1.34B | $1.44B | $1.16B |
Other Non-Current Assets | $6.42B | $1.84B | $1.04B | $1.66B | $2.08B |
Total Non-Current Assets | $62.82B | $63.39B | $69.55B | $76.05B | $88.29B |
Other Assets | $- | $- | $- | $- | $- |
Total Assets | $92.60B | $95.16B | $96.82B | $109.31B | $118.48B |
Account Payables | $3.60B | $3.26B | $3.04B | $2.95B | $2.71B |
Short Term Debt | $2.05B | $3.28B | $4.40B | $5.12B | $2.50B |
Tax Payables | $- | $1.37B | $942.00M | $754.00M | $647.00M |
Deferred Revenue | $- | $271.00M | $1.34B | $3.69B | $3.62B |
Other Current Liabilities | $18.13B | $14.35B | $13.51B | $13.05B | $13.22B |
Total Current Liabilities | $23.77B | $22.26B | $21.89B | $21.87B | $19.08B |
Long Term Debt | $47.60B | $38.18B | $36.32B | $40.48B | $49.17B |
Deferred Revenue Non-Current | $- | $300.00M | $283.00M | $326.00M | $357.00M |
Deferred Tax Liabilities Non-Current | $369.00M | $338.00M | $2.17B | $4.50B | $5.41B |
Other Non-Current Liabilities | $4.47B | $4.59B | $5.05B | $6.13B | $6.59B |
Total Non-Current Liabilities | $52.44B | $43.41B | $43.81B | $51.44B | $61.52B |
Other Liabilities | $- | $- | $- | $- | $- |
Total Liabilities | $76.22B | $65.67B | $65.70B | $73.31B | $80.60B |
Preferred Stock | $- | $- | $- | $- | $- |
Common Stock | $292.00M | $292.00M | $292.00M | $292.00M | $292.00M |
Retained Earnings | $14.91B | $28.77B | $25.50B | $23.82B | $21.28B |
Accumulated Other Comprehensive Income Loss | $-1.24B | $-1.55B | $-1.28B | $-1.27B | $-1.84B |
Other Total Stockholders Equity | $2.37B | $1.92B | $6.55B | $13.10B | $18.09B |
Total Stockholders Equity | $16.34B | $29.43B | $31.06B | $35.95B | $37.82B |
Total Equity | $16.39B | $29.48B | $31.12B | $36.01B | $37.88B |
Total Liabilities and Stockholders Equity | $92.60B | $95.16B | $96.82B | $109.31B | $118.48B |
Minority Interest | $53.00M | $55.00M | $57.00M | $60.00M | $60.00M |
Total Liabilities and Total Equity | $92.60B | $95.16B | $96.82B | $109.31B | $118.48B |
Total Investments | $513.00M | $3.31B | $2.32B | $5.96B | $5.79B |
Total Debt | $49.65B | $41.46B | $40.72B | $45.60B | $51.67B |
Net Debt | $39.30B | $30.00B | $31.59B | $31.62B | $37.13B |
Balance Sheet Charts
Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash and Cash Equivalents | $7.89B | $6.29B | $9.33B | $11.46B | $7.51B | $8.37B | $8.99B | $9.12B | $7.73B | $10.75B | $12.37B | $13.98B | $13.54B | $11.02B | $10.98B | $14.55B | $19.43B | $19.93B | $15.82B | $12.35B |
Short Term Investments | $204.00M | $360.00M | $340.00M | $816.00M | $171.00M | $358.00M | $274.00M | $130.00M | $1.29B | $2.52B | $2.83B | $3.24B | $2.28B | $2.99B | $2.15B | $1.28B | $1.85B | $1.86B | $2.50B | $3.05B |
Cash and Short Term Investments | $8.09B | $6.66B | $9.67B | $12.28B | $7.68B | $8.37B | $8.99B | $9.12B | $9.03B | $13.27B | $15.20B | $13.98B | $15.82B | $14.02B | $13.14B | $14.55B | $21.28B | $21.79B | $18.32B | $12.35B |
Net Receivables | $14.89B | $15.15B | $14.06B | $15.26B | $15.65B | $15.06B | $13.40B | $13.94B | $13.24B | $12.54B | $11.10B | $12.52B | $11.74B | $11.28B | $8.66B | $8.50B | $8.06B | $7.86B | $8.29B | $7.68B |
Inventory | $3.33B | $3.08B | $2.98B | $2.66B | $2.44B | $2.36B | $2.60B | $2.34B | $2.07B | $2.14B | $2.10B | $2.10B | $2.16B | $2.14B | $1.95B | $2.07B | $1.95B | $2.38B | $2.84B | $4.29B |
Other Current Assets | $1.75B | $2.01B | $1.95B | $1.56B | $1.86B | $1.92B | $1.75B | $1.74B | $2.46B | $2.24B | $1.72B | $1.29B | $1.72B | $1.73B | $3.36B | $5.58B | $2.98B | $2.31B | $2.40B | $1.98B |
Total Current Assets | $28.07B | $26.89B | $28.67B | $31.77B | $27.63B | $28.07B | $27.09B | $27.27B | $26.80B | $30.19B | $30.12B | $33.26B | $31.44B | $29.16B | $27.11B | $30.19B | $34.28B | $34.34B | $31.85B | $29.35B |
Property Plant Equipment Net | $8.25B | $8.16B | $8.19B | $8.04B | $7.85B | $7.63B | $7.61B | $7.47B | $6.92B | $6.81B | $6.94B | $6.97B | $6.83B | $6.80B | $6.61B | $6.75B | $6.46B | $5.78B | $6.11B | $6.25B |
Goodwill | $21.75B | $21.73B | $21.74B | $21.17B | $21.15B | $21.16B | $21.16B | $21.15B | $21.11B | $20.45B | $20.50B | $20.50B | $20.52B | $20.53B | $20.52B | $20.55B | $20.52B | $20.58B | $22.45B | $22.49B |
Intangible Assets | $26.96B | $29.84B | $33.17B | $27.48B | $29.38B | $31.77B | $34.05B | $36.35B | $38.73B | $38.26B | $40.42B | $42.77B | $44.93B | $48.06B | $50.82B | $53.24B | $56.70B | $59.17B | $61.67B | $63.97B |
Goodwill and Intangible Assets | $48.72B | $51.57B | $54.91B | $48.65B | $50.52B | $52.94B | $55.22B | $57.50B | $59.84B | $58.71B | $60.92B | $63.28B | $65.45B | $68.59B | $71.34B | $73.79B | $77.22B | $79.75B | $84.12B | $86.46B |
Long Term Investments | $2.85B | $3.00B | $2.23B | $2.06B | $1.88B | $1.99B | $2.00B | $2.19B | $1.96B | $1.97B | $2.19B | $2.71B | $4.78B | $3.77B | $4.64B | $4.51B | $4.66B | $4.41B | $651.00M | $767.00M |
Tax Assets | $3.61B | $3.32B | $2.72B | $2.77B | $1.51B | $1.57B | $1.32B | $1.34B | $1.33B | $1.34B | $1.42B | $1.44B | $684.00M | $650.00M | $793.00M | $1.16B | $913.00M | $1.09B | $605.00M | $510.00M |
Other Non-Current Assets | $2.17B | $1.70B | $2.32B | $1.87B | $1.86B | $1.29B | $1.05B | $1.04B | $1.36B | $1.34B | $1.45B | $1.66B | $1.70B | $1.83B | $1.94B | $2.08B | $2.01B | $2.71B | $5.95B | $6.60B |
Total Non-Current Assets | $65.59B | $67.76B | $70.36B | $63.39B | $63.63B | $65.42B | $67.19B | $69.55B | $71.40B | $70.17B | $72.91B | $76.05B | $79.45B | $81.64B | $85.32B | $88.29B | $91.26B | $93.73B | $97.43B | $100.59B |
Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Total Assets | $93.67B | $94.65B | $99.03B | $95.16B | $91.26B | $93.49B | $94.28B | $96.82B | $98.20B | $100.36B | $103.03B | $109.31B | $110.89B | $110.80B | $112.44B | $118.48B | $125.54B | $128.08B | $129.28B | $129.94B |
Account Payables | $3.47B | $3.75B | $3.54B | $3.26B | $2.81B | $3.07B | $3.19B | $3.04B | $2.60B | $2.88B | $2.94B | $2.95B | $2.69B | $3.61B | $2.97B | $2.71B | $2.44B | $2.85B | $3.07B | $2.44B |
Short Term Debt | $1.24B | $3.71B | $6.36B | $3.28B | $5.62B | $3.19B | $2.92B | $4.40B | $2.30B | $5.12B | $7.69B | $5.12B | $5.24B | $2.83B | $1.94B | $2.50B | $3.72B | $4.95B | $4.00B | $3.48B |
Tax Payables | $1.49B | $1.47B | $1.49B | $1.37B | $1.46B | $1.53B | $1.21B | $942.00M | $1.29B | $1.14B | $930.00M | $754.00M | $751.00M | $638.00M | $716.00M | $647.00M | $686.00M | $2.27B | $2.00B | $1.52B |
Deferred Revenue | $- | $2.69B | $3.86B | $4.22B | $3.87B | $3.79B | $- | $1.34B | $1.33B | $3.44B | $- | $1.44B | $3.36B | $3.01B | $3.01B | $1.16B | $3.18B | $4.61B | $4.10B | $510.00M |
Other Current Liabilities | $16.44B | $14.33B | $14.44B | $14.35B | $13.57B | $12.37B | $11.76B | $13.51B | $12.75B | $11.77B | $11.25B | $13.05B | $12.78B | $11.92B | $11.71B | $13.22B | $13.62B | $13.34B | $10.17B | $10.86B |
Total Current Liabilities | $22.64B | $23.27B | $25.82B | $22.26B | $23.46B | $20.15B | $19.09B | $21.89B | $18.93B | $20.91B | $22.82B | $21.87B | $21.46B | $18.99B | $17.33B | $19.08B | $20.46B | $23.42B | $19.23B | $18.30B |
Long Term Debt | $50.16B | $50.30B | $51.05B | $38.18B | $33.65B | $36.00B | $36.45B | $36.32B | $37.81B | $37.92B | $38.30B | $40.48B | $40.61B | $43.47B | $45.33B | $49.17B | $42.09B | $42.56B | $43.53B | $44.06B |
Deferred Revenue Non-Current | $247.00M | $263.00M | $282.00M | $300.00M | $316.00M | $305.00M | $308.00M | $283.00M | $296.00M | $307.00M | $319.00M | $326.00M | $340.00M | $324.00M | $340.00M | $357.00M | $361.00M | $377.00M | $394.00M | $424.00M |
Deferred Tax Liabilities Non-Current | $430.00M | $461.00M | $442.00M | $338.00M | $399.00M | $751.00M | $1.57B | $2.17B | $2.88B | $3.03B | $3.81B | $4.50B | $4.96B | $4.93B | $5.24B | $5.41B | $5.91B | $6.16B | $6.53B | $6.45B |
Other Non-Current Liabilities | $3.00B | $3.29B | $4.89B | $4.59B | $4.37B | $4.25B | $4.99B | $5.05B | $5.54B | $5.52B | $6.14B | $6.13B | $6.25B | $6.21B | $6.53B | $6.59B | $6.48B | $6.41B | $9.62B | $9.01B |
Total Non-Current Liabilities | $53.83B | $54.31B | $56.66B | $43.41B | $38.74B | $41.31B | $43.31B | $43.81B | $46.53B | $46.78B | $48.57B | $51.44B | $52.15B | $54.93B | $57.43B | $61.52B | $54.84B | $55.49B | $60.08B | $59.94B |
Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Total Liabilities | $76.47B | $77.58B | $82.48B | $65.67B | $62.20B | $61.46B | $62.40B | $65.70B | $65.46B | $67.70B | $71.39B | $73.31B | $73.61B | $73.92B | $74.76B | $80.60B | $75.31B | $78.92B | $79.31B | $78.25B |
Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Common Stock | $292.00M | $292.00M | $292.00M | $292.00M | $292.00M | $292.00M | $292.00M | $292.00M | $292.00M | $292.00M | $292.00M | $292.00M | $292.00M | $292.00M | $292.00M | $292.00M | $292.00M | $292.00M | $292.00M | $292.00M |
Retained Earnings | $16.10B | $16.10B | $15.64B | $28.77B | $28.22B | $27.45B | $26.57B | $25.50B | $24.68B | $24.22B | $23.95B | $23.82B | $22.62B | $22.17B | $22.20B | $21.28B | $32.41B | $31.57B | $32.67B | $34.47B |
Accumulated Other Comprehensive Income Loss | $-1.47B | $-1.46B | $-1.40B | $-1.55B | $-1.29B | $-1.39B | $-1.37B | $-1.28B | $-841.00M | $-992.00M | $-1.23B | $-1.27B | $-1.42B | $-1.52B | $-1.54B | $-1.84B | $-1.70B | $-1.56B | $-1.55B | $-1.52B |
Other Total Stockholders Equity | $2.22B | $2.08B | $1.96B | $1.92B | $1.77B | $5.62B | $6.33B | $6.55B | $8.54B | $9.08B | $8.57B | $13.10B | $15.72B | $15.87B | $16.65B | $18.09B | $19.15B | $18.79B | $18.50B | $18.35B |
Total Stockholders Equity | $17.14B | $17.02B | $16.49B | $29.43B | $29.00B | $31.97B | $31.82B | $31.06B | $32.67B | $32.60B | $31.58B | $35.95B | $37.21B | $36.81B | $37.60B | $37.82B | $50.16B | $49.09B | $49.91B | $51.60B |
Total Equity | $17.20B | $17.07B | $16.55B | $29.48B | $29.06B | $32.03B | $31.89B | $31.12B | $32.73B | $32.66B | $31.64B | $36.01B | $37.28B | $36.87B | $37.67B | $37.88B | $50.23B | $49.16B | $49.98B | $51.70B |
Total Liabilities and Stockholders Equity | $93.67B | $94.65B | $99.03B | $95.16B | $91.26B | $93.49B | $94.28B | $96.82B | $98.20B | $100.36B | $103.03B | $109.31B | $110.89B | $110.80B | $112.44B | $118.48B | $125.54B | $128.08B | $129.28B | $129.94B |
Minority Interest | $58.00M | $54.00M | $58.00M | $55.00M | $64.00M | $57.00M | $62.00M | $57.00M | $63.00M | $61.00M | $65.00M | $60.00M | $71.00M | $66.00M | $68.00M | $60.00M | $72.00M | $66.00M | $66.00M | $100.00M |
Total Liabilities and Total Equity | $93.67B | $94.65B | $99.03B | $95.16B | $91.26B | $93.49B | $94.28B | $96.82B | $98.20B | $100.36B | $103.03B | $109.31B | $110.89B | $110.80B | $112.44B | $118.48B | $125.54B | $128.08B | $129.28B | $129.94B |
Total Investments | $3.06B | $3.36B | $340.00M | $2.88B | $171.00M | $358.00M | $2.28B | $2.32B | $3.25B | $4.49B | $5.01B | $5.96B | $7.07B | $6.76B | $6.79B | $6.41B | $6.51B | $6.27B | $3.16B | $3.81B |
Total Debt | $51.40B | $54.00B | $57.41B | $41.46B | $39.27B | $39.19B | $39.37B | $40.72B | $40.11B | $43.04B | $45.99B | $45.60B | $45.84B | $46.29B | $47.27B | $51.67B | $45.81B | $47.51B | $47.53B | $47.54B |
Net Debt | $43.51B | $47.71B | $48.08B | $30.00B | $31.75B | $30.81B | $30.38B | $31.59B | $32.38B | $32.29B | $33.63B | $31.62B | $32.30B | $35.27B | $36.29B | $37.13B | $26.37B | $27.58B | $31.71B | $35.19B |
Annual Cash Flow
Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
---|---|---|---|---|---|
Net Income | $-8.93B | $8.04B | $6.34B | $7.01B | $-8.99B |
Depreciation and Amortization | $9.60B | $9.76B | $10.28B | $10.69B | $10.38B |
Deferred Income Tax | $-2.09B | $-3.29B | $-2.74B | $-1.39B | $983.00M |
Stock Based Compensation | $507.00M | $518.00M | $457.00M | $583.00M | $779.00M |
Change in Working Capital | $- | $-1.91B | $-2.23B | $-1.25B | $983.00M |
Accounts Receivables | $264.00M | $-995.00M | $-663.00M | $-2.12B | $-2.95B |
Inventory | $-486.00M | $-751.00M | $-69.00M | $13.00M | $2.67B |
Accounts Payables | $184.00M | $198.00M | $109.00M | $245.00M | $188.00M |
Other Working Capital | $- | $-366.00M | $-1.61B | $606.00M | $1.07B |
Other Non Cash Items | $16.11B | $744.00M | $955.00M | $570.00M | $9.92B |
Net Cash Provided by Operating Activities | $15.19B | $13.86B | $13.07B | $16.21B | $14.05B |
Investments in Property Plant and Equipment | $-1.25B | $-1.21B | $-1.12B | $-973.00M | $-753.00M |
Acquisitions Net | $-21.82B | $-260.00M | $-2.98B | $-862.00M | $-12.21B |
Purchases of Investments | $-769.00M | $-1.77B | $-3.59B | $-5.48B | $-4.17B |
Sales Maturities of Investments | $1.39B | $948.00M | $6.63B | $6.78B | $6.28B |
Other Investing Activities | $1.10B | $- | $4.34B | $2.04B | $2.98B |
Net Cash Used for Investing Activities | $-21.35B | $-2.29B | $-1.06B | $-538.00M | $-10.86B |
Debt Repayment | $- | $456.00M | $-5.31B | $-6.02B | $3.93B |
Common Stock Issued | $- | $- | $- | $- | $- |
Common Stock Repurchased | $- | $-5.16B | $-8.00B | $-6.29B | $-1.55B |
Dividends Paid | $-4.86B | $-4.74B | $-4.63B | $-4.40B | $-4.08B |
Other Financing Activities | $9.99B | $27.00M | $984.00M | $481.00M | $542.00M |
Net Cash Used Provided by Financing Activities | $5.13B | $-9.42B | $-16.96B | $-16.22B | $-1.15B |
Effect of Forex Changes on Cash | $-137.00M | $45.00M | $-33.00M | $-102.00M | $111.00M |
Net Change in Cash | $-1.17B | $2.19B | $-4.99B | $-657.00M | $2.15B |
Cash at End of Period | $10.35B | $11.52B | $9.32B | $14.32B | $14.97B |
Cash at Beginning of Period | $11.52B | $9.32B | $14.32B | $14.97B | $12.82B |
Operating Cash Flow | $15.19B | $13.86B | $13.07B | $16.21B | $14.05B |
Capital Expenditure | $-1.25B | $-1.21B | $-1.12B | $-973.00M | $-753.00M |
Free Cash Flow | $13.94B | $12.65B | $11.95B | $15.23B | $13.30B |
Cash Flow Charts
Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | $1.22B | $1.68B | $-11.91B | $1.76B | $1.93B | $2.08B | $2.27B | $2.02B | $1.61B | $1.43B | $1.28B | $2.37B | $1.55B | $1.06B | $2.03B | $-10.03B | $1.88B | $-80.00M | $-766.00M | $-1.06B |
Depreciation and Amortization | $2.59B | $2.56B | $2.53B | $2.46B | $2.44B | $2.43B | $2.43B | $2.52B | $2.59B | $2.58B | $2.58B | $2.58B | $2.73B | $2.71B | $2.67B | $2.69B | $2.65B | $2.56B | $2.48B | $1.24B |
Deferred Income Tax | $-256.00M | $-331.00M | $-711.00M | $-1.33B | $-327.00M | $-1.09B | $-548.00M | $-624.00M | $-645.00M | $-782.00M | $-687.00M | $-1.27B | $-32.00M | $-163.00M | $68.00M | $-436.00M | $54.00M | $1.42B | $-53.00M | $-337.00M |
Stock Based Compensation | $129.00M | $125.00M | $133.00M | $127.00M | $132.00M | $137.00M | $122.00M | $119.00M | $115.00M | $116.00M | $107.00M | $133.00M | $142.00M | $157.00M | $151.00M | $171.00M | $185.00M | $213.00M | $210.00M | $284.00M |
Change in Working Capital | $1.71B | $-2.37B | $198.00M | $855.00M | $291.00M | $-1.70B | $-1.36B | $-458.00M | $164.00M | $-1.57B | $-362.00M | $-56.00M | $650.00M | $-1.41B | $-434.00M | $-154.00M | $-1.29B | $1.14B | $1.28B | $1.84B |
Accounts Receivables | $661.00M | $-1.02B | $479.00M | $536.00M | $-659.00M | $-2.18B | $-175.00M | $-106.00M | $-557.00M | $-669.00M | $786.00M | $-646.00M | $-306.00M | $-1.72B | $67.00M | $-646.00M | $-2.45B | $502.00M | $-743.00M | $752.00M |
Inventory | $-218.00M | $-225.00M | $-218.00M | $-197.00M | $-256.00M | $-16.00M | $-282.00M | $-41.00M | $-16.00M | $-13.00M | $1.00M | $-128.00M | $30.00M | $5.00M | $106.00M | $101.00M | $481.00M | $642.00M | $1.45B | $470.00M |
Accounts Payables | $-374.00M | $-259.00M | $300.00M | $444.00M | $-268.00M | $-165.00M | $187.00M | $405.00M | $-300.00M | $-19.00M | $23.00M | $226.00M | $-139.00M | $-145.00M | $303.00M | $132.00M | $-424.00M | $-223.00M | $703.00M | $181.00M |
Other Working Capital | $1.64B | $-868.00M | $-1.27B | $72.00M | $1.47B | $665.00M | $-1.09B | $-716.00M | $1.04B | $329.00M | $-1.17B | $492.00M | $1.06B | $442.00M | $-910.00M | $259.00M | $1.10B | $220.00M | $-126.00M | $442.00M |
Other Non Cash Items | $204.00M | $7.41B | $12.97B | $371.00M | $286.00M | $27.00M | $60.00M | $-277.00M | $-143.00M | $370.00M | $887.00M | $295.00M | $227.00M | $706.00M | $-658.00M | $11.43B | $-1.27B | $-981.00M | $744.00M | $70.00M |
Net Cash Provided by Operating Activities | $5.59B | $2.33B | $2.83B | $4.25B | $4.75B | $1.89B | $2.97B | $3.31B | $3.69B | $2.26B | $3.81B | $4.06B | $5.27B | $3.06B | $3.82B | $3.67B | $2.22B | $4.27B | $3.89B | $2.04B |
Investments in Property Plant and Equipment | $-324.00M | $-262.00M | $-284.00M | $-330.00M | $-342.00M | $-259.00M | $-278.00M | $-346.00M | $-247.00M | $-272.00M | $-253.00M | $-320.00M | $-270.00M | $-210.00M | $-173.00M | $-283.00M | $-153.00M | $-131.00M | $-186.00M | $-251.00M |
Acquisitions Net | $-859.00M | $-1.10B | $-19.81B | $-340.00M | $-79.00M | $10.00M | $149.00M | $374.00M | $-3.04B | $-275.00M | $-40.00M | $26.00M | $-869.00M | $-569.00M | $550.00M | $-12.34B | $-41.00M | $-10.00M | $180.00M | $-10.81B |
Purchases of Investments | $-40.00M | $-84.00M | $-274.00M | $-717.00M | $-502.00M | $-355.00M | $-200.00M | $-26.00M | $-274.00M | $-1.58B | $-1.71B | $-2.07B | $-1.06B | $-1.04B | $-1.30B | $-1.02B | $-1.19B | $-1.22B | $-735.00M | $-2.32B |
Sales Maturities of Investments | $238.00M | $130.00M | $752.00M | $41.00M | $513.00M | $275.00M | $119.00M | $1.21B | $1.48B | $1.84B | $2.10B | $2.77B | $1.23B | $2.00B | $782.00M | $1.52B | $1.22B | $2.14B | $1.39B | $1.34B |
Other Investing Activities | $766.00M | $316.00M | $241.00M | $-435.00M | $258.00M | $114.00M | $146.00M | $1.68B | $1.43B | $450.00M | $790.00M | $873.00M | $351.00M | $756.00M | $65.00M | $819.00M | $231.00M | $1.06B | $864.00M | $12.79B |
Net Cash Used for Investing Activities | $-219.00M | $-1.32B | $-19.62B | $-1.35B | $-410.00M | $-329.00M | $-210.00M | $1.21B | $-2.08B | $-289.00M | $95.00M | $401.00M | $-976.00M | $180.00M | $-143.00M | $-12.13B | $-165.00M | $780.00M | $653.00M | $-12.04B |
Debt Repayment | $-2.65B | $-2.80B | $15.95B | $2.10B | $-10.00M | $-124.00M | $-1.51B | $136.00M | $-2.86B | $-2.79B | $199.00M | $-114.00M | $-361.00M | $-1.12B | $-4.52B | $5.69B | $-1.74B | $-48.00M | $- | $4.00M |
Common Stock Issued | $- | $- | $- | $-10.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Common Stock Repurchased | $- | $- | $- | $- | $-4.00B | $-905.00M | $-250.00M | $-2.42B | $-585.00M | $- | $-5.00B | $-2.75B | $-525.00M | $-1.24B | $-1.77B | $-1.47B | $- | $- | $-81.00M | $-7.00B |
Dividends Paid | $-1.22B | $-1.22B | $-1.21B | $-1.16B | $-1.19B | $-1.20B | $-1.20B | $-1.15B | $-1.15B | $-1.15B | $-1.19B | $-1.10B | $-1.09B | $-1.10B | $-1.11B | $-1.02B | $-1.02B | $-1.02B | $-1.02B | $-668.00M |
Other Financing Activities | $16.00M | $-6.00M | $-97.00M | $25.00M | $41.00M | $53.00M | $-92.00M | $179.00M | $53.00M | $419.00M | $333.00M | $-3.00M | $196.00M | $276.00M | $110.00M | $277.00M | $171.00M | $76.00M | $44.00M | $-13.00M |
Net Cash Used Provided by Financing Activities | $-3.85B | $-4.02B | $14.64B | $967.00M | $-5.16B | $-2.17B | $-3.05B | $-3.25B | $-4.54B | $-3.52B | $-5.65B | $-3.97B | $-1.78B | $-3.18B | $-7.29B | $3.48B | $-2.59B | $-993.00M | $-1.05B | $-7.68B |
Effect of Forex Changes on Cash | $77.00M | $-22.00M | $-45.00M | $78.00M | $-38.00M | $-8.00M | $13.00M | $95.00M | $-66.00M | $-71.00M | $9.00M | $-54.00M | $-28.00M | $18.00M | $-38.00M | $87.00M | $31.00M | $60.00M | $-67.00M | $6.00M |
Net Change in Cash | $1.60B | $-3.04B | $-2.19B | $3.95B | $-857.00M | $-623.00M | $-277.00M | $1.37B | $-3.00B | $-1.62B | $-1.74B | $437.00M | $2.48B | $76.00M | $-3.65B | $-4.89B | $-502.00M | $4.12B | $3.43B | $-17.67B |
Cash at End of Period | $7.89B | $6.29B | $9.33B | $11.52B | $7.57B | $8.43B | $9.05B | $9.32B | $7.96B | $10.96B | $12.58B | $14.32B | $13.88B | $11.40B | $11.32B | $14.97B | $19.86B | $20.36B | $16.25B | $12.82B |
Cash at Beginning of Period | $6.29B | $9.33B | $11.52B | $7.57B | $8.43B | $9.05B | $9.32B | $7.96B | $10.96B | $12.58B | $14.32B | $13.88B | $11.40B | $11.32B | $14.97B | $19.86B | $20.36B | $16.25B | $12.82B | $30.49B |
Operating Cash Flow | $5.59B | $2.33B | $2.83B | $4.25B | $4.75B | $1.89B | $2.97B | $3.31B | $3.69B | $2.26B | $3.81B | $4.06B | $5.27B | $3.06B | $3.82B | $3.67B | $2.22B | $4.27B | $3.89B | $2.04B |
Capital Expenditure | $-324.00M | $-262.00M | $-284.00M | $-330.00M | $-342.00M | $-259.00M | $-278.00M | $-346.00M | $-247.00M | $-272.00M | $-253.00M | $-320.00M | $-270.00M | $-210.00M | $-173.00M | $-283.00M | $-153.00M | $-131.00M | $-186.00M | $-251.00M |
Free Cash Flow | $5.27B | $2.06B | $2.55B | $3.92B | $4.41B | $1.63B | $2.69B | $2.96B | $3.44B | $1.99B | $3.56B | $3.74B | $5.00B | $2.85B | $3.65B | $3.39B | $2.07B | $4.14B | $3.71B | $1.79B |
Bristol-Myers Squibb Stock Forecast
Analyst ratings, price targets, and earnings estimates for BMY.
BMY Analyst Ratings
Hold
Based on 20 analysts in the past 3 months
BMY Stock 12 Month Forecast
$53.43
Based on 7 analysts in the last year
Recent Price Targets
Recommendation Trends
Analyst Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Latest Price Target Updates
Date | Analyst | Firm | Price Target | Price When Posted | Upside |
---|---|---|---|---|---|
Nov 12, 2024 | Evan Seigerman | BMO Capital | $61.00 | $56.23 | 8.5% |
Nov 01, 2024 | Evan David Seigerman | BMO Capital | $57.00 | $54.32 | 4.9% |
Sep 23, 2024 | Evan David Seigerman | BMO Capital | $48.00 | $49.56 | -3.1% |
Jul 29, 2024 | Chris Shibutani | Goldman Sachs | $57.00 | $50.55 | 12.8% |
Jul 29, 2024 | Carter Gould | Barclays | $41.00 | $50.45 | -18.7% |
Jul 12, 2024 | Trung Huynh | UBS | $43.00 | $40.68 | 5.7% |
May 16, 2024 | Steve Scala | Cowen & Co. | $67.00 | $44.11 | 51.9% |
Jan 30, 2024 | James Shin | Deutsche Bank | $55.00 | $49.87 | 10.3% |
Nov 27, 2023 | Evan Seigerman | BMO Capital | $60.00 | $49.76 | 20.6% |
Oct 12, 2023 | David Risinger | Leerink Partners | $66.00 | $56.25 | 17.3% |
Bristol-Myers Squibb Dividends
Explore Bristol-Myers Squibb's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
4.24%
Dividend Payout Ratio
-54.35%
Dividend Paid & Capex Coverage Ratio
2.49x
Bristol-Myers Squibb Dividend History
Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
---|---|---|---|---|---|
$0.62 | $0.62 | January 03, 2025 | January 03, 2025 | February 03, 2025 | December 11, 2024 |
$0.6 | $0.6 | October 04, 2024 | October 04, 2024 | November 01, 2024 | September 10, 2024 |
$0.6 | $0.6 | July 05, 2024 | July 05, 2024 | August 01, 2024 | June 18, 2024 |
$0.6 | $0.6 | April 04, 2024 | April 05, 2024 | May 01, 2024 | March 01, 2024 |
$0.6 | $0.6 | January 04, 2024 | January 05, 2024 | February 01, 2024 | December 06, 2023 |
$0.57 | $0.57 | October 05, 2023 | October 06, 2023 | November 01, 2023 | September 20, 2023 |
$0.57 | $0.57 | July 06, 2023 | July 07, 2023 | August 01, 2023 | June 14, 2023 |
$0.57 | $0.57 | April 06, 2023 | April 10, 2023 | May 01, 2023 | March 03, 2023 |
$0.57 | $0.57 | January 05, 2023 | January 06, 2023 | February 01, 2023 | December 08, 2022 |
$0.54 | $0.54 | October 06, 2022 | October 07, 2022 | November 01, 2022 | September 14, 2022 |
$0.54 | $0.54 | June 30, 2022 | July 01, 2022 | August 01, 2022 | June 15, 2022 |
$0.54 | $0.54 | March 31, 2022 | April 01, 2022 | May 02, 2022 | March 01, 2022 |
$0.54 | $0.54 | January 06, 2022 | January 07, 2022 | February 01, 2022 | December 13, 2021 |
$0.49 | $0.49 | September 30, 2021 | October 01, 2021 | November 01, 2021 | September 09, 2021 |
$0.49 | $0.49 | July 01, 2021 | July 02, 2021 | August 02, 2021 | June 17, 2021 |
$0.49 | $0.49 | March 31, 2021 | April 01, 2021 | May 03, 2021 | March 01, 2021 |
$0.49 | $0.49 | December 31, 2020 | January 04, 2021 | February 01, 2021 | December 10, 2020 |
$0.45 | $0.45 | October 01, 2020 | October 02, 2020 | November 02, 2020 | September 10, 2020 |
$0.45 | $0.45 | July 02, 2020 | July 06, 2020 | August 03, 2020 | June 11, 2020 |
$0.45 | $0.45 | April 02, 2020 | April 03, 2020 | May 01, 2020 | March 02, 2020 |
Peers: Drug Manufacturers - General
This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.
Company | Market Cap | Price | EPS | P/E Ratio | P/B Ratio |
---|---|---|---|---|---|
![]() AbbVie Inc.
ABBV
|
$340.83B | $192.87 | $2.75 | $56.34 | $26.45 |
![]() Merck & Co., Inc.
MRK
|
$209.99B | $83.01 | $0.14 | $778.71 | $7.56 |
![]() Gilead Sciences, Inc.
GILD
|
$129.71B | $104.08 | $0.38 | $239.97 | $0.00 |
![]() Johnson & Johnson
JNJ
|
$375.95B | $156.15 | $5.84 | $24.53 | $27385.90 |
![]() Eli Lilly and Company
LLY
|
$801.48B | $844.27 | $11.71 | $65.93 | $48.75 |
![]() Pfizer Inc.
PFE
|
$144.68B | $25.53 | $1.42 | $18.71 | $1.62 |
![]() Amgen Inc.
AMGN
|
$156.51B | $291.16 | $7.56 | $34.48 | $23.99 |
![]() Biogen Inc.
BIIB
|
$20.01B | $137.33 | $11.20 | $13.65 | $1.33 |
Related Metrics
Explore detailed financial metrics and analysis for BMY.